



## Practical Insights in Novel Immune Therapies in Multiple Myeloma

NOVEMBER 2, 2022 | VIRTUAL

### DRAFT PROGRAM AGENDA

6:00-6:05 PM	<b>Welcome</b> Nikhil Munshi
6:05-6:17 PM	<b>Overview of immune therapies and CAR T cells: Defining the unmet need in relapsed refractory multiple myeloma; MOA of CAR T cells and TCEs and clinical data</b> Nikhil Munshi
6:17-6:19 PM	<b>Case study</b> Presenter TBD
6:19-6:25 PM	<b>Panel Discussion</b> Moderator: Nikhil Munshi
6:25-6:37 PM	<b>Patients and the process – defining patient selection for TCEs/CAR T cell therapy in practice - Understanding of CAR T eligibility to ensure the right patient is referred for CAR T therapy</b> Melissa Alsina
6:37-6:39 PM	<b>Case study</b> Presenter TBD
6:39-6:45 PM	<b>Panel Discussion</b> Moderator: Melissa Alsina
6:45-6:57 PM	<b>Managing TCE/CAR T cell toxicities: Practical tips for short and long-term adverse events associated with CAR T cell therapy (focus on needs for coordination between community centers and CAR T centers)</b> Ajai Chari
6:57-6:59 PM	<b>Case study</b> Presenter TBD
6:59-7:05 PM	<b>Panel Discussion</b> Moderator: Ajai Chari
7:05-7:17 PM	<b>Managing relapse following novel immune therapies and Future advances</b> Noopur Raje
7:17-7:19 PM	<b>Case study</b> Presenter TBD
7:19-7:25 PM	<b>Panel Discussion</b> Moderator: Noopur Raje
7:25-7:30 PM	<b>Wrap-Up</b>

**TO REGISTER:** <https://www.eventcreate.com/e/imsedseries>

Registration is complimentary.

The International Myeloma Society gratefully acknowledges the following organizations for their support of the workshop:



Supported by a grant from Pfizer Inc.

